Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist ...

Core Insights - Polyrizon Ltd. has announced significant results from ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform [1][2][3] Group 1: Study Findings - The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, using excised rabbit nasal mucosa to simulate human nasal tissues [2] - Advanced ex vivo studies showed that Polyrizon's formulation spreads rapidly and uniformly across the nasal mucosa, forming a consistent surface layer [3] - Mucoadhesion testing indicated that the formulation maintains strong attachment to nasal tissue, even under conditions simulating physiological nasal fluid flow, supporting prolonged efficacy [3][4] Group 2: Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens [5] - The proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and prolonged retention for drug delivery [5] - An additional technology, Trap and Target (T&T), is in pre-clinical development focused on nasal delivery of active pharmaceutical ingredients [5]

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurolo ...

Core Viewpoint - Polyrizon Ltd. has announced a successful preliminary safety study for its PL-14 Allergy Blocker, marking a significant advancement in the product's development path [1][5]. Group 1: Study Details - The safety study was conducted on fully differentiated human nasal tissue using the MucilAir™ model, demonstrating strong local tolerability [2]. - The study assessed local tolerance and tissue response after a 4-hour application of PL-14, a mucoadhesive nasal gel spray designed to act as a physical barrier against airborne allergens [3]. - Key safety indicators evaluated included tissue integrity (TEER), cytotoxicity (LDH), cilia beating frequency (CBF), mucociliary clearance (MCC), and inflammatory response (IL-8 secretion), with results showing no signs of inflammatory activation or functional impairment [4]. Group 2: Regulatory and Development Plans - The results of the study are a milestone in validating the local safety of PL-14 and support the company's clinical development plans [5]. - The data will aid in the regulatory strategy and support an upcoming FDA pre-submission meeting, with U.S. and European clinical trials expected to begin in late 2025 or early 2026 [6]. Group 3: Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [7]. - The company is developing its proprietary Capture and Contain (C&C) hydrogel technology, which aims to enhance bioadhesion and prolonged retention for intranasal drug delivery [7].

Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide. Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel te ...

The offering consisted of the sale of 35,416,667 Ordinary Units (or Pre-Funded Units), each consisting of (i) one (1) Ordinary Share or Pre-Funded Warrant, and (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant. The offering price per Ordinary Unit was $0.48 (or $0.47999 for each Pre-Funded Unit, which is equal to the offering price per Ordinary Unit sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be exercisable followi ...

The securities described above are being sold in a private placement transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Th ...

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced the structuring of its clinical strategy for PL-14, the Company’s proprietary intranasal allergy blocker for seasonal allergic rhinitis. The clinical strategy was updated in preparation for a planned pre-submission meet ...

Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurolog ...

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyri ...